Author

A. Zutz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Organism:E. coli· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

C. Schölz· 2 shared L. Chen· 2 shared A. Koza· 1 shared A. T. Nielsen· 1 shared C. Choudhary· 1 shared E. Papaleo· 1 shared F. Sippl· 1 shared H. Blum· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

C. Schölz

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A dual-reporter system for investigating and optimizing protein translation and folding in E. coli

A. Zutz, L. Hamborg, L. E. Pedersen, M. M. Kassem, E. Papaleo, A. Koza, M. J. Herrgard, K. Teilum, K. Lindorff-Larsen, A. T. Nielsen

This paper introduces a dual-reporter system to assess protein translation and folding in E. coli, validated on five proteins with good correlation between reporter signals and protein expression/solubility.

bioRxiv · Sep 18, 2020Biochemistry

Epigenetic compound screening uncovers small molecules for re-activation of latent HIV-1

A. Zutz, L. Chen, F. Sippl, C. Schölz

This study screens epigenetic compounds to identify new latency reversing agents (LRAs) for reactivating latent HIV-1, finding two novel compounds with high reactivation efficiency and low toxicity.

bioRxiv · Aug 21, 2020Pharmacology & Toxicology

Histone deacetylase inhibitors butyrate and bufexamac inhibit de novo HIV-1 infection in CD4 T-cells

C. Schölz, L. Chen, A. Zutz, O. T. Keppler, J. Philippou-Massier, H. Blum, T. Liebner, C. Choudhary

This study shows that HDAC inhibitors butyrate and bufexamac inhibit de novo HIV-1 infection in CD4 T-cells without reactivating latent virus.

bioRxiv · Apr 29, 2020 · PreprintMicrobiology